Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. - Spring LM; Tolaney SM; Fell G; Bossuyt V; Abelman RO; Wu B; Maheswaran S; Trippa L; Comander A; Mulvey T; McLaughlin S; Ryan P; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2024)